Bringing the Oncology Community Together

Melanoma and Skin Cancer

Latest Melanoma and Skin Cancer Articles View more >>
Novel Immunotherapeutic Safe and Effective in Early-Phase Melanoma Study
Novel Immunotherapeutic Safe and Effective in Early-Phase Melanoma Study
A novel immunotherapeutic known as IMCgp100 induced clinical responses with manageable toxicity in patients with advanced melanoma
Long-Term Outcomes Support Sentinel-Node Biopsy for Staging Melanoma
Long-Term Outcomes Support Sentinel-Node Biopsy for Staging Melanoma
A 10-year follow-up study of regional melanoma staging strategies found that patients who underwent sentinel-node biopsies had significantly greater disease-free survival rates (DFSRs) compared with patients monitored through nodal observation.
Durable T-VEC Responses Fail to Prolong Survival in Updated Analysis
Durable T-VEC Responses Fail to Prolong Survival in Updated Analysis
Talimogene laherparepvec significantly improved durable response rates but failed to extend overall survival in patients with advanced melanoma.
PD-L1 Predictive of Response to MK-3475 in Melanoma and NSCLC
PD-L1 Predictive of Response to MK-3475 in Melanoma and NSCLC
PD-L1 levels adequately predict response and clinical outcomes for PD-1 inhibitor MK-3475 in patients with non-small cell lung cancer (NSCLC) and melanoma
T-VEC Promotes Tumor Shrinkage in Unresectable Melanoma
T-VEC Promotes Tumor Shrinkage in Unresectable Melanoma
The oncolytic immunotherapeutic vaccine talimogene laherparepvec (T-VEC) promoted tumor shrinkage in 64% of patients with advanced melanoma, including a marked reduction in the size of uninjected metastatic lesions
Publications
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.